PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Researchers develop terahertz biosensor to detect skin cancer for early diagnosis

Results from the study could also be used for other forms of cancer and diseases.

Researchers from the University of Glasgow and Queen Mary University of London have developed a new biosensor using terahertz (THz) waves that can detect skin cancer with strong sensitivity.

Published in the IEEE Transactions on Biomedical Engineering, the study results could pave the way for easier and earlier diagnoses of skin cancer and potentially other cancers and diseases.

Affecting one in four men and one in five women at least once in their lifetime in the UK, skin cancer is an abnormal growth of skin cells that involves three major types: basal cell carcinoma (BCC), squamous cell carcinoma and melanoma.

Most skin cancer is often detected using traditional methods that involve expensive, time-consuming CT and PET scans, and invasive higher-frequency technology.

After exploring the potential of THz metasurfaces, researchers designed the biosensor to detect subtle changes in cell properties, featuring small, asymmetric resonators on a flexible substrate, to analyse a combination of parameters including resonance frequency, transmission magnitude and a value called Full Width at Half Maximum.

The biosensor provides a more in-depth picture of the tissue to allow more accurate differentiation between healthy and cancerous cells, as well as measuring the malignancy degree of the tissues.

Researchers revealed that the biosensor successfully differentiated between normal skin cells and BCC cells, even at different concentrations.

Professor Qammer Abbasi, co-director for communication sensing and imaging hub at the University of Glasgow’s James Watt School of Engineering, said: “Integrating [THz] imaging technology into this type of flexible, portable, reusable sensor could make cancer screening a quicker and more comfortable procedure for patients.

“The implications of this study extend far beyond skin cancer detection,” said Dr Shohreh Nourinovin, postdoctoral research association, Queen Mary’s School of Electronic Engineering and Computer Science.

She added: “This technology could be used for early detection of various cancers and other diseases, like Alzheimer’s, with potential applications in resource-limited settings due to its portability and affordability.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026